CN105085503A - Medicine composition for treating respiratory tract infection - Google Patents
Medicine composition for treating respiratory tract infection Download PDFInfo
- Publication number
- CN105085503A CN105085503A CN201510602545.4A CN201510602545A CN105085503A CN 105085503 A CN105085503 A CN 105085503A CN 201510602545 A CN201510602545 A CN 201510602545A CN 105085503 A CN105085503 A CN 105085503A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- tract infection
- compound
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 NC(C12)=N*C1=CC=CC2c1ccc2[o]c(Nc3ccccc3)nc2c1 Chemical compound NC(C12)=N*C1=CC=CC2c1ccc2[o]c(Nc3ccccc3)nc2c1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine composition for treating a respiratory tract infection. The medicine composition comprises an effective quantity of compounds and carriers capable of being accepted in pharmacy. The compounds are of the structure (please see the specification for the structure). The compounds of the medicine composition have the remarkable effect on pathogenic bacteria causing the respiratory tract infection and can be developed into the novel medicine composition effective in clinic.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of respiratory tract infection.
Background technology
Respiratory tract infection is common clinical frequently-occurring disease, and the cause of disease is many caused by cause pathogeny imcrobe infection, causes the pathogenic micro-organism of fever to mainly contain bacterium, virus, mycoplasma, chlamydozoan.Modern medicine thinks that definite pathogenesis still imperfectly understands, and is the result of many factors comprehensive action, and immunologic hypofunction is considered to one of major reason of falling ill.In prior art, (1) Physical temperature-lowering is roughly, as warm water or alcohol bath, ice bag cooling, normal saline enema etc. to the methods for the treatment of research of diseases caused by external factors fever; (2) drug cooling, as oral febrifugee, Metamizole nasal drip or the medicine such as intramuscular injection, intravenous drip dexamethasone, takes antimicrobial agents to treat infection simultaneously; (3) herbal treatment: as oral traditional Chinese medicine preparation, the external application of Chinese medicine etc.
The common virus of respiratory tract infection is caused to have influenza virus, rhinovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus etc., wherein common with rhinovirus.Find after deliberation, in the saliva of the children's of respiratory tract infection, various pathogens detected, find that in the recent period teacher hilllock streptomycete ATCC19166 is also one of pathogenic bacterium wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of respiratory tract infection.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of respiratory tract infection, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of respiratory tract infection, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment respiratory tract infection, and this compound has having structure:
Preferably, described respiratory tract infection Shi Youshi hilllock streptomycete ATCC19166 causes.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition teacher hilllock streptomycete ATCC19166, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogenic bacteria Be very effective causing respiratory tract infection, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition teacher hilllock streptomycete ATCC19166
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of compound is:
(Shanghai) bio tech ltd is sent purchased from logical for examination bacterial classification teacher hilllock streptomycete ATCC19166.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Teacher hilllock streptomycete ATCC19166 is inoculated in agar plate nutritive medium plane, evenly gathers during inoculation.
Take target compound 0.1 gram, add 5000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The mean diameter of the bacterial restrain of teacher hilllock streptomycete ATCC19166 is 14.56mm, and this shows that target compound has the effect of extremely strong suppression teacher hilllock streptomycete ATCC19166.
Claims (9)
1. treat a compound for respiratory tract infection, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for respiratory tract infection, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of respiratory tract infection according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of respiratory tract infection according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of respiratory tract infection according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of respiratory tract infection according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment respiratory tract infection, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described respiratory tract infection Shi Youshi hilllock streptomycete ATCC19166 causes.
9. the purposes of compound in the medicine of preparation vitro inhibition teacher hilllock streptomycete ATCC19166, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510602545.4A CN105085503A (en) | 2015-09-20 | 2015-09-20 | Medicine composition for treating respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510602545.4A CN105085503A (en) | 2015-09-20 | 2015-09-20 | Medicine composition for treating respiratory tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105085503A true CN105085503A (en) | 2015-11-25 |
Family
ID=54566919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510602545.4A Pending CN105085503A (en) | 2015-09-20 | 2015-09-20 | Medicine composition for treating respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105085503A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687189A (en) * | 2016-03-08 | 2016-06-22 | 高芳 | Medicine composition for treating upper respiratory tract infection |
| CN106038557A (en) * | 2016-07-18 | 2016-10-26 | 李振芳 | Medicine for treating rheumatoid arthritis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573846A (en) * | 2009-08-17 | 2012-07-11 | 因特利凯公司 | Heterocyclic compounds and uses thereof |
| CN104204804A (en) * | 2011-11-11 | 2014-12-10 | 因特利凯有限责任公司 | Combinations of kinase inhibitors and uses thereof |
-
2015
- 2015-09-20 CN CN201510602545.4A patent/CN105085503A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573846A (en) * | 2009-08-17 | 2012-07-11 | 因特利凯公司 | Heterocyclic compounds and uses thereof |
| CN104204804A (en) * | 2011-11-11 | 2014-12-10 | 因特利凯有限责任公司 | Combinations of kinase inhibitors and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| M. ANGELS ESTIARTE,ET AL.: ""2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH)"", 《MED. CHEM. COMMUN.》 * |
| 李影林，等: "《临床医学检验手册》", 31 March 1989 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687189A (en) * | 2016-03-08 | 2016-06-22 | 高芳 | Medicine composition for treating upper respiratory tract infection |
| CN106038557A (en) * | 2016-07-18 | 2016-10-26 | 李振芳 | Medicine for treating rheumatoid arthritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN110974819B (en) | Composition for upper respiratory tract infection and application thereof | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105503880A (en) | Medicine composition for treating respiratory diseases | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105232550A (en) | Drug combination for treating chronic pelvic inflammatory disease | |
| CN105330610A (en) | Medicine composition for treating gingivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |